Goelzer Investment Management Inc. Sells 198 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Goelzer Investment Management Inc. decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 19,754 shares of the medical research company’s stock after selling 198 shares during the period. Goelzer Investment Management Inc.’s holdings in IQVIA were worth $3,882,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IQV. Private Trust Co. NA lifted its stake in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares in the last quarter. Clear Harbor Asset Management LLC lifted its position in shares of IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock worth $941,000 after purchasing an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co boosted its holdings in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after purchasing an additional 50 shares during the last quarter. Fortitude Family Office LLC grew its position in IQVIA by 2.9% in the third quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock valued at $468,000 after purchasing an additional 56 shares in the last quarter. Finally, Huntington National Bank increased its stake in IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after buying an additional 56 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Morgan Stanley dropped their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Stock Performance

IQV opened at $204.54 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The business has a fifty day simple moving average of $199.47 and a 200 day simple moving average of $221.09. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a market capitalization of $37.12 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.